Projection of the clinical and economic burden of chronic kidney disease between 2022 and 2027 in Spain: Results of the Inside CKD project.

Autor:	Navarro González JF; Unidad de Investigación y Servicio de Nefrología, Hospital Universitario Nuestra Señora de Candelaria, Tenerife, Spain; RICORS2040 (Kidney Disease), Instituto de Salud Carlos III, Madrid, Spain; Instituto de Tecnologías Biomédicas, Universidad de La Laguna, Tenerife, Spain; Universidad Fernando Pessoa Canarias, Las Palmas de Gran Canaria, Spain., Ortiz A; Servicio de Nefrología e Hipertensión, IIS-Fundación Jiménez Díaz UAM, Madrid, Spain., Cebrián Cuenca A; Medicina Familiar y Comunitaria, Centro de Salud Cartagena Casco Antiguo, Cartagena, Spain; Grupo de Atención Primaria del Instituto Murciano de Investigación Biosanitaria (IMIB), Murcia, Spain., Moreno Barón M; Asociación para la Lucha Contra las Enfermedades Renales (ALCER), Almería, Spain., Segú L; Unidad de Farmacia Clínica y Farmacoterapia, Facultad de Farmacia, Universidad de Barcelona (UB), Barcelona, Spain; Acceso al Mercado, PharmaLex Spain, Barcelona, Spain., Pimentel B; Médico, AstraZeneca, Madrid, Spain., Aranda U; Global Medical Affairs, BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, MD, United States., Lopez-Chicheri B; Acceso al Mercado, AstraZeneca, Madrid, Spain., Capel M; Acceso al Mercado, AstraZeneca, Madrid, Spain., Pomares Mallol E; Acceso al Mercado, PharmaLex Spain, Barcelona, Spain., Caudron C; Acceso al Mercado, PharmaLex Spain, Barcelona, Spain., García Sánchez JJ; Health Economics, BioPharmaceuticals Medical, AstraZeneca, Cambridge, United Kingdom. Electronic address: juanjose.garciasanchez@astrazeneca.com., Alcázar Arroyo R; Servicio de Nefrología, Hospital Universitario Infanta Leonor, Madrid, Spain.
Jazyk:	angličtina
Zdroj:	Nefrologia [Nefrologia (Engl Ed)] 2024 Dec 03. Date of Electronic Publication: 2024 Dec 03.
DOI:	10.1016/j.nefroe.2024.11.009
Abstrakt:	Background and Objective: Chronic kidney disease (CKD) is a growing health problem affecting between 10% and 15% of the Spanish population. The lack of updated projections of the evolution of the disease burden hinders the development of evidence-based health policies and interventions to optimise the management of the disease and prevent its progression. The aim of this study is to project the evolution of the clinical and economic burden of CKD in Spain between 2022 and 2027. Materials and Methods: Inside CKD uses a validated microsimulation approach to project the burden of CKD. The projection is based on a virtual population according to Spanish demographics, literature, national data registries and clinical expert opinion. Costs associated with CKD management, renal replacement therapy (RRT), cardiovascular complications and arterial comorbidities were included. Results: In Spain, an absolute increase in the prevalence of CKD of 1% (from 10.7% to 11.7%) is expected between 2022 and 2027, corresponding to an increase from 5.14 million to 5.68 million patients in 2027. However, only one third of CKD patients would be diagnosed. Of these diagnosed patients, 3.9% will require RRT in 2027, an increase of 14.7% from 2022. A total of 654,281 accumulated deaths are expected in patients with CKD diagnosed between 2022 and 2027. The economic burden of diagnosed CKD is expected to increase by 13.8% to 4.89 billion euros in 2027, representing 5.56% of total Spanish public health expenditure in 2027 (compared to 4.88% in 2022), of which 42.5% will be allocated to RRT (2.4% of public health expenditure). Conclusions: The Inside CKD project highlights the growing clinical, economic and social burden of CKD in Spain expected by 2027. Progression to more advanced stages with the need for RRT and associated complications represent a small proportion of the total CKD population, but contribute significantly to overall costs. Competing Interests: Declaration of competing interest BL, UA, BLC, MC and JJGS are employees of AstraZeneca. LS, EPM and CC are employees of PharmaLex. AO has received grants from Sanofi and fees for consultations or conferences, or travel expenses from Adviccene, Alexion, Astellas, AstraZeneca, Amicus, Amgen, Boehringer Ingelheim, Fresenius Medical Care, GSK, Bayer, Sanofi-Genzyme, Menarini, Mundipharma, Kyowa Kirin, Lilly, Freeline, Idorsia, Chiesi, Otsuka, Novo-Nordisk, Sysmex and Vifor Fresenius Medical Care Renal Pharma. In addition, AO is director of the UAM-AstraZeneca Chair of chronic kidney disease and electrolytes, and has shares in Telara Farma. (Copyright © 2024 Sociedad Española de Nefrología. Published by Elsevier España, S.L.U. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu